PDF Cover

Drug Eluting Stents Market

The market for Drug Eluting Stents was estimated at $7.6 billion in 2024; it is anticipated to increase to $12.6 billion by 2030, with projections indicating growth to around $19.4 billion by 2035.

Report ID:DS1801199
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Drug Eluting Stents
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Drug Eluting Stents Market Outlook

Revenue, 2024

$7.6B

Forecast, 2034

$17.8B

CAGR, 2025 - 2034

8.9%

The Drug Eluting Stents industry revenue is expected to be around $8.3 billion in 2025 and expected to showcase growth with 8.9% CAGR between 2025 and 2034. The significant growth in this area can be credited to a variety of factors that have been supporting the rise in the market over time. The increasing occurrence of heart diseases globally and an aging demographic more prone to ailments along with a growing trend, towards less invasive procedures are driving the importance of Drug Eluting Stents forward. They have become a part of contemporary cardiovascular care as they can prevent arteries from narrowing again after angioplasty and lower the chances of restenosis occurring. Furthermore the advancement of cutting edge technologies supported by research and development efforts has driven the markets robust expansion and sustained significance.

Among the advancements in the field of healthcare are Drug Eluting Stents that are implanted during surgeries to clear blockages in arteries and improve blood flow smoothly again. They come with a coating of drugs that are released gradually to prevent a common issue called restenosis where arteries become narrow again. They are commonly used in treating heart diseases well as peripheral artery conditions and during procedures, like coronary artery interventions.

Drug Eluting Stents market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Drug Eluting Stents Market Outlook

Market Key Insights

  • The Drug Eluting Stents market is projected to grow from $7.6 billion in 2024 to $17.8 billion in 2034. This represents a CAGR of 8.9%, reflecting rising demand across Coronary Artery Disease, Peripheral Artery Disease, and Venous Thrombosis.

  • Abbott Laboratories, Medtronic, and Boston Scientific are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Drug Eluting Stents market and are expected to observe the growth CAGR of 6.5% to 9.3% between 2024 and 2030.

  • Emerging markets including Indonesia, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 8.5% to 11.1%.

  • Transition like Advancements in Biomaterials is expected to add $1 billion to the Drug Eluting Stents market growth by 2030

    .

  • The Drug Eluting Stents market is set to add $10.2 billion between 2024 and 2034, with manufacturer targeting Peripheral Artery Disease & Femoropopliteal Artery Application projected to gain a larger market share.

  • With

    increasing cardiovascular diseases worldwide, and

    Technological Advancements in Interventional Cardiology, Drug Eluting Stents market to expand 135% between 2024 and 2034.

drug eluting stents market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Drug Eluting Stents - Country Share Analysis

Opportunities in the Drug Eluting Stents

Growing markets such as India China and Brazil present promising growth prospects for the DES industry. As these nations prioritize enhancing their healthcare systems the need for medical equipment, like DES is also projected to increase.

Growth Opportunities in North America and Asia Pacific

The thriving healthcare and medical device industry in North America supports a market for Drug Eluting Stents due to the high occurrence of cardiovascular diseases in the region and an educated consumer base driving market expansion forward. The presence of healthcare facilities and major industry players contributes to a highly competitive market environment. Factors propelling the growth of this market include a rising population, high rates of obesity and an increasing preference, for minimally invasive medical procedures. Advancements in stent technology and the increasing use supported by medical insurance coverage present promising avenues, for future growth.
The Asia Pacific region holds promise for the Drug Eluting Stents market with a growing population and increasing cases of lifestyle diseases contributing to its potential growth opportunities. With domestic manufacturers entering the market intensifying competition slowly and healthcare expenditure expanding along with government regulations creating conducive environments for market expansion. The rising trend of tourism in countries like India and China is a significant factor driving growth as they evolve into destinations, for cost effective yet top notch medical services. The demand for healthcare in rural regions and the increasing recognition of the advantages of Drug Eluting Stents present promising avenues, for development.

Market Dynamics and Supply Chain

01

Driver: Increasing Cardiovascular Diseases Worldwide, and Growing Elderly Population and Associated Health Complications

The increasing prevalence of heart diseases globally has also led to a demand for more sophisticated medical treatments such as heart surgeries and interventions to address the issue effectively. This notable uptick in heart related conditions is also proving to be pivotal for the Drug Eluting Stents industry. These specialized stents are also crafted to tackle blockages in the arteries and are also gaining popularity due, to their effectiveness and positive treatment results.

The expanding elderly population globally is also another factor for the Drug Eluting Stents market to consider. The aging process is also often linked with an occurrence of heart related issues and illnesses. The demand for less invasive heart therapies provided by Drug Eluting Stents becomes much more crucial within this age group. This increasing healthcare requirements of this demographic indicate opportunities for growth, in the Drug Eluting Stents sector.

In times there have also been significant technological advancements in the field of interventional cardiology with the introduction of new DES technologies that offer better drug delivery and lower risks of complications – factors that have also led to their increased use in healthcare facilities worldwide. The industry has also experienced growth due to enhancements in stent design and the shift, towards using polymers as key innovations.

02

Restraint: High Manufacturing Cost and Regulatory Challenges

The creation of Drug Coated Stents requires technology and costly materials with strict quality measures in place which result in elevated production expenses that are then transferred to consumers thereby impeding market expansion growth for these products furthermore regulatory challenges like meeting the demanding approval criteria set by bodies such as the FDA act as barriers, to introducing new inventive drug coated stents into the market thereby restricting its growth potential.

03

Opportunity: Strategic Collaborations and Technological Innovations

In order to remain competitive in the Drug Eluting Stents sector manufacturers are forming strategic alliances and working together with research institutions and healthcare organizations. These partnerships are focused on creating cutting edge stent technologies and introducing therapeutic uses. By collaborating in this way parties involved can meet the changing demands of the healthcare field while promoting the expansion and acceptance of Drug Eluting Stents.

As medical technology progresses further into the future there are increasing prospects for Drug Eluting Stents in the field of invasive procedures. Technological advancements like polymers have shown great promise in improving the efficiency of Drug Eluting Stents, which helps lower restenosis rates effectively. This presents an outlook, for meeting future market needs especially for patients looking for efficient and gentler treatment choices.

04

Challenge: Slow Adoption in Emerging Economies

In developing countries with a number of patients in need of medical treatment the uptake of DES has been sluggish compared to other regions. This can be attributed to reasons including limited knowledge about the advantages of these stents inadequate healthcare facilities to promote their widespread adoption and financial constraints faced by individuals with lower incomes. These factors contribute to the demand, for DES hindering the expansion of the market in these regions.

Supply Chain Landscape

1

Raw Material Procurement

Carpenter Technology CorporationATI Specialty Alloys & Components
2

Medical Device Manufacturing

MedtronicAbbott Laboratories
3

Device Sterilization & Packaging

STERIS CorporationSotera Health
4

Distribution & Sales

Cardinal HealthMcKesson Corporation
Drug Eluting Stents - Supply Chain

Use Cases of Drug Eluting Stents in Coronary Artery Disease & Venous Thrombosis

Coronary Artery Disease : Coronary artery disease is still a common use case for Drug Eluting Stents that are specially crafted to prevent blockages in arteries after angioplasty by releasing medication to reduce the chances of restenosis occurring over time. Leading companies in this field, like Boston Scientific and Medtronic leverage nanotechnology and polymer based products to strengthen their market presence and stay competitive.
Peripheral Artery Disease : DES are also beneficial for treating artery disease—a common practice region where they help prevent arteries in the heart or limbs from narrowing again after treatment procedures like angioplasty or stenting are done by companies such, as Abbott Laboratories who focus on developing bioresorbable stents that dissolve in the body naturally over time.
Venous Thrombosis : When dealing with thrombosis cases Drug Eluting Venous Stents are used to improve blood flow and reduce the risk of blood clots forming. Companies like Cook Medical are leading the way in developing stents that enhance patient results and solidify their position, in the market.

Recent Developments

The healthcare sector on a scale has experienced notable progress in the field of cardiovascular treatments with a special focus on the evolution of Drug Eluting Stents . Through dedicated research efforts and technological enhancements in DES technology such as resorbable materials and improved drug delivery mechanisms for anti restenosis benefits have been achieved which confirms its significant role, in contemporary cardiac treatment practices.

December 2024 : Boston Scientific Corporation, a manufacturer and market leader of Drug Eluting Stents unveiled a new stent made with nanolayer polymer technology with the goal of lowering restensosis rates.
November 2024 : Medtronic introduced a Drug Eluting Stent featuring sirolimus to improve patient results.
September 2024 : Johnson & Johnson introduced their Drug Eluting Stent that utilizes biodegradable technology. This represents an advancement, in the treatment of coronary artery disease.

Impact of Industry Transitions on the Drug Eluting Stents Market

As a core segment of the Medical Device industry, the Drug Eluting Stents market develops in line with broader industry shifts. Over recent years, transitions such as Advancements in Biomaterials and Growing Adoption of DES in Emerging Economies have redefined priorities across the Medical Device sector, influencing how the Drug Eluting Stents market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Advancements in Biomaterials

The DES market is undergoing a significant transformation driven by advancements in biomaterials, which are projected to contribute an additional $1 billion to market growth by 2030. The integration of innovative polymer and polymer-free designs has not only improved biocompatibility, reducing the risk of late stent thrombosis, but has also elevated patient outcomes. This strategic shift is fostering heightened competition and innovation among manufacturers, positioning them to capitalize on the growing demand for safer, more effective stent technologies. As the market evolves, companies that leverage these advancements will be better positioned to capture market share and drive future growth. This industry transition is expected to add $1 billion in the industry revenue between 2024 and 2030.
02

Growing Adoption of DES in Emerging Economies

A significant shift in the drug coated stent industry is the rising popularity of these devices in developing nations like India and Brazil due to their proven effectiveness in preventing artery re narrowings compared to bare metal stents This surge is driven by improvements in healthcare facilities and rising rates of heart related ailments, in these areas creating opportunities for stent makers to expand their market share and grow their business.

Related Reports
Loading related reports...